• KOLs Community
    • Ritalin
    • Ritalin Concerta
    • Rafael Muniz
    • Rafael Muniz

      Rafael Muniz

      Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ. | From the ...



      KOL Resume for Rafael Muniz


      Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ.


      From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Centers, LLC, Little Rock, AR; ∥Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV; ¶Biostatistics, US Medical; and #Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.


      US Clinical Developmental & Medical Affairs, Neuroscience, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA


      Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.


      Novartis Pharmaceuticals Corporation, East Hanover, New Jersey


      Norvartis Pharmaceuticals, East Hanover, New Jersey.

      Dr. Greenhill is with the Research Unit of Pediatric Psychopharmacology at the New York State Psychiatric Institute, New York; Dr. Muniz is with USCD and MA; Ms. Pestreich and Dr. Jiang are with Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dr. Ball is with the CNS Research Institute, Philadelphia; Dr. Levine is with the University of Colorado Health Sciences Center and the Alpine Clinical Research Center, Boulder.


      Novartis Pharmaceutical, East Hanover, New Jersey


      Novartis Pharmaceuticals Corporation, Children's Developmental Center, Maitland, Florida. *



      Rafael Muniz: Influence Statistics

      Sample of concepts for which Rafael Muniz is among the top experts in the world.
      Concept World rank
      concerta 18mg #3
      18mg concerta #3


      Prominent publications by Rafael Muniz

      KOL-Index: 72724

      ObjectivesThe primary objective was to compare the differences in clinical efficacy of the starting dose of Ritalin® LA™ (20mg) to the starting dose of Concerta® (18mg), in a laboratory school setting for the duration of an entire school day. Secondary objectives were to compare Ritalin® LA™ 20mg with Concerta® 36mg, and Ritalin® LA™ and both Concerta® doses versus placebo across the school day.MethodsThirty-six children (29 males, 7 females), aged 6–12 years, with attention deficit ...

      Known for Ritalin Concerta | School Day | Attention Deficit | Comparative Efficacy | Response Relationship
      KOL-Index: 14104

      Objective: To compare the rate and extent of absorption of DL-threo-methylphenidate (MPH) from two modified-release MPH formulations at their respective recommended starting doses in healthy adult volunteers.Design: Open-label, randomised, crossover, bioavailability study.Participants: Twenty healthy adult male and female volunteers.Methods: Subjects received single doses of two modified-release formulations of MPH, a 20mg capsule (Ritalin® LA) and an 18mg tablet (Concerta®). A total of ...

      Known for Oral Administration | Release Formulations | Healthy Adults | Ritalin Concerta | Absorption Mph
      KOL-Index: 11194

      OBJECTIVE: This study compared the efficacy and safety of extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day and 30 mg/day with extended-release racemic methylphenidate hydrochloride (d,l-MPH-ER) 36 mg/day and 54 mg/day, and placebo in children with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting.

      METHODS: This multicenter, double-blind, crossover study included children (N = 84) 6-12 years of age, stabilized on total daily doses of 40 mg to 60 mg ...

      Known for Hyperactivity Disorder | Placebo Children | Classroom Study | Release Dexmethylphenidate | Efficacy Safety
      KOL-Index: 10241

      Background: Long-acting methylphenidate formulations provide control of attention-deficit hyperactivity disorder (ADHD) symptoms for up to 12 hours; however, not all formulations have rapid onset of therapeutic effect, which is essential for providing symptom control during morning hours. The primary objective of this randomized, double-blind, crossover study was to assess the efficacy of dexmethylphenidate extended release (ER) versus placebo by measuring the change from pre-dose to 0.5 ...

      Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose | Laboratory Classroom
      KOL-Index: 9720

      OBJECTIVE: The aim of this study was to assess changes in symptomatology of attention-deficit/ hyperactivity disorder (ADHD) with extended-release dexmethylphenidate (d-MPHER) versus placebo in a laboratory classroom setting.

      METHODS: This double-blind, placebo-controlled, crossover study randomized 54 children 6-12 years of age, stabilized on methylphenidate 20-40 mg/day. Patients participated in a practice day, then received 5 days of treatment with d-MPH-ER 20 mg/day or placebo. After ...

      Known for Hyperactivity Disorder | Children Adhd | Child Cross | 20 Day Placebo | Release Dexmethylphenidate
      KOL-Index: 9697

      BACKGROUND: This multicenter, randomized, fixed-dose, double-blind, placebo-controlled study evaluated efficacy of extended-release dexmethylphenidate (d-MPH-ER) in adults with attention-deficit/hyperactivity disorder (ADHD).

      METHODS: Randomized adults with ADHD (n=221) received once-daily d-MPH-ER 20 mg, 30 mg, or 40 mg or placebo for 5 weeks. The primary efficacy variable was change from baseline to final visit in DSM-IV ADHD Rating Scale (ADHD-RS) total score. Secondary efficacy ...

      Known for Hyperactivity Disorder | Adults Adhd | Dexmethylphenidate Extended | Illness Surveys | Total Score
      KOL-Index: 9686

      OBJECTIVE: The aim of this study was to compare efficacy and safety of two long-acting formulations of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) in school-age children.

      METHODS: Children 6-12 years of age diagnosed with ADHD and stabilized on MPH (20-40 mg/day) participated in a five-way, randomized, placebo-controlled, single-blind, crossover study conducted in a laboratory classroom setting. Children alternately received single doses of extended-release ...

      Known for Laboratory Classroom Setting | Hyperactivity Disorder | Methylphenidate Formulations | Efficacy Safety | Oros Mph
      KOL-Index: 8483

      OBJECTIVE: This study compared once-daily dexmethylphenidate extended release (D-MPH-ER) 20 mg/day and placebo over 12 hours in children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting.

      METHOD: All of the children were stabilized for > or =2 weeks on a total dose (nearest equivalent) MPH 40 mg/day or immediate-release D-MPH 20 mg/day before screening. After a practice day, they received 6 days of D-MPH-ER 20 mg/day or placebo at home, ...

      Known for Hyperactivity Disorder | 12 Hours | Children Attention | Child Cross | Dexmethylphenidate Extended
      KOL-Index: 7886

      OBJECTIVE: The efficacy and safety of dexmethylphenidate extended release (d-MPH-ER) was compared to placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD).

      METHOD: This multicenter, randomized, double-blind, placebo-controlled, parallel-group, two-phase study included 97 patients (ages 6-17 years) with DSM-IV-defined ADHD. The study was carried out between 2001 and 2003. After a 2-week evaluation phase, patients were randomized to d-MPH-ER or placebo for 7 ...

      Known for Hyperactivity Disorder | Adhd Children | Efficacy Safety | Dexmethylphenidate Extended | Attention Deficit
      KOL-Index: 7256

      The objective of this study was to evaluate the safety and efficacy of dexmethylphenidate extended-release (d-MPH-ER) 30 versus 20 mg in children with attention-deficit/hyperactivity disorder (ADHD) in a 12-hour laboratory classroom setting. In a randomized, double-blind, 3-period × 3-treatment, crossover study, children aged 6 to 12 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-diagnosed ADHD previously stabilized on MPH (40-60 mg/d) or D-MPH (20-30 ...

      Known for Hyperactivity Disorder | 30 Mph | Versus 20 | Attention Deficit | 165 Children
      KOL-Index: 6929

      dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. It had been exclusively available in the racemic form, i.e., a 50:50 mixture of d- and l-isomers. However, a single enantiomer formulation, d-MPH (dexmethylphenidate), became available for general clinical use in 2002. For this reason, the intrinsic pharmacological differences in the effects of d- and l-MPH have recently come under intense investigation. The ...

      Known for Lmph Mph | Serotonin 5 | Transport Proteins | Plasma Membrane | Central Nervous
      KOL-Index: 6880

      OBJECTIVE: This study evaluates dexmethylphenidate extended release (d-MPH-ER) in adults with ADHD.

      METHOD: Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults entered a 6-month open-label extension (OLE) to assess long-term safety, with flexible dosing of 20 to 40 mg/d. Exploratory effectiveness outcomes included change from Week 5 on ADHD Rating Scale (ADHD-RS) and proportion of responders on Clinical Global Impressions-Improvement (CGI-I) ...

      Known for Adult Adhd | Dexmethylphenidate Extended | Mph 20 | Longterm Safety | Term Treatment
      KOL-Index: 5654

      Methylphenidate (MPH, Ritalin), has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the FDA over 50 years ago. Diagnoses of pediatric patients with ADHD and the administration of MPH to treat the symptoms have increased in prevalence in recent years. A 2005 study by El-Zein et al. reported statistically significant increases in cytogenetic anomalies including chromosomal aberrations (CA), micronuclei (MN) and sister chromatid exchanges ...

      Known for Hyperactivity Disorder | Attention Deficit | Behavior Therapy | Peripheral Blood | 3 Months
      KOL-Index: 5037

      OBJECTIVE: This 5-week, multicenter, double-blind, placebo-controlled, parallel-group investigation is the first fixed-dose study to evaluate efficacy and tolerability of three doses of (10, 20, or 30 mg, once daily [o.d.]) dexmethylphenidate hydrochloride (HCl) extended-release (d-MPH XR; Focalin XR) across multiple settings to treat pediatric attention-deficit/hyperactivity disorder (ADHD).

      RESULTS: ADHD pediatric outpatients (n = 253) diagnosed according to Diagnostic and Statistical ...

      Known for Dexmethylphenidate Extended | Hyperactivity Disorder | Attention Deficit | Adhd Symptoms | Drug Administration

      Key People For Ritalin Concerta

      Top KOLs in the world
      James M Swanson
      hyperactivity disorder children adhd attention deficit
      Timothy Edwin Wilens
      bipolar disorder attention deficit adults adhd
      Laurence Lee Greenhill
      hyperactivity disorder suicidal behavior children adhd
      Oscar Gary Bukstein
      practice parameter substance abuse hyperactivity disorder
      Sharon B Wigal
      hyperactivity disorder children adhd attention deficit
      Suneel K Gupta
      nicotine transdermal consultancy funding fentanyl hcl
      Select a search phrase   ritalin concerta

      Rafael Muniz:Expert Impact

      Concepts for whichRafael Munizhas direct influence:Ritalin concerta,  Hyperactivity disorder,  Laboratory classroom setting,  Concerta ritalin,  Crossover study,  Child cross,  Disorder hyperactivity,  School day.

      Rafael Muniz:KOL impact

      Concepts related to the work of other authors for whichfor which Rafael Muniz has influence:Hyperactivity disorder,  Attention deficit,  Adults adhd,  Lisdexamfetamine dimesylate,  Methylphenidate mph,  Children adolescents,  Nervous stimulants.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ. | From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston;

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.